Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of sonesitatug vedotin-based regimens versus standard of care in CLDN18.2-positive gastric, gastroesophageal junction, and distal esophageal adenocarcinoma
NL-OMON61282Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of sonesitatug vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (5 cohorts), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON61282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61282.